Annual Report 2022

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2022 89 The United Laboratories International Holdings Limited Annual Report 2022 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (a) Segment revenue and results (Continued) Year ended 31 December 2021 Intermediate Bulk Finished Segment products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 1,700,337 3,968,575 4,034,526 9,703,438 – 9,703,438 Inter-segment sales 1,684,837 585,413 – 2,270,250 (2,270,250) – Segment revenue 3,385,174 4,553,988 4,034,526 11,973,688 (2,270,250) 9,703,438 RESULT Segment profit 396,151 202,220 875,571 1,473,942 Unallocated other income 147,311 Unallocated corporate expenses (106,227) Unallocated other gains and losses, net 41,799 Impairment losses recognised under expected credit loss model, net of reversal (293,947) Finance costs (60,231) Profit before taxation 1,202,647